Compare EHang Holdings Ltd - ADR (EH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Merck & Co., Inc. — how do they compare? EHang Holdings Ltd - ADR trades at $4.09 (market cap $314.00M), while Merck & Co., Inc. trades at $141.84 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 1121.9× EHang Holdings Ltd - ADR's market cap, and Merck & Co., Inc. pays a 2.38% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Merck & Co., Inc. for 98 Days on average.
| EH | MRK | |
|---|---|---|
Market Cap | $314.00M | $352.29B |
Volume | 856,650 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $18.94 | $156.43 |
52-Week Low | $4.03 | $82.49 |
Typical Hold Time | 46 Days | 98 Days |
Enterprise Value | $265.69M | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical outlook and mixed financials. Revenue declined to $418M in 2025 with a net loss of $276M, though gross margins remain strong at 61.5%. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a cautious sentiment.
The outlook is challenged by persistent losses and regulatory scrutiny, but the company's cash position of $1.12B provides some buffer. Investment opportunities lie in the nascent eVTOL market, while risks include execution missteps and intense competition. Analyst consensus is divided, reflecting high uncertainty.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
